- |||||||||| EPC-002 / Elpis Biopharma
Journal: Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates. (Pubmed Central) - Jun 14, 2023 The in vitro mycobacterial growth inhibition assay demonstrated that EPCP009m inhibited Mycobacterium tuberculosis (Mtb) growth most strongly, followed by EPCP009f, which was significantly better than that of the other four vaccine candidates. These results indicated that EPCP009m containing four immunodominant antigens exhibited better immunogenicity and Mtb growth inhibition in vitro and may be a promising candidate vaccine for the control of TB.
- |||||||||| Opdivo (nivolumab) / BMS, Zepzelca (lurbinectedin) / PharmaMar, Jazz, Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 9, 2023 P1/2, N=40, Recruiting, These results indicated that EPCP009m containing four immunodominant antigens exhibited better immunogenicity and Mtb growth inhibition in vitro and may be a promising candidate vaccine for the control of TB. Not yet recruiting --> Recruiting
- |||||||||| rotigotine XR microspheres (LY03003) / Luye Group
Trial completion, Trial completion date: A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD (clinicaltrials.gov) - May 6, 2023 P3, N=294, Completed, Tdv ameliorated cerebral ischemic injury through reducing neuronal apoptosis and increasing the expression of BDNF via the activation of CREB pathway. Recruiting --> Completed | Trial completion date: May 2022 --> Sep 2022
- |||||||||| Lipusu (liposomal paclitaxel) / Luye Group
Journal: Transforming a Toxic Non-Ionizable Drug into an Efficacious Liposome via Ionizable Prodrug and Remote Loading Strategies against Malignant Breast Tumors. (Pubmed Central) - May 2, 2023 Due to its non-ionizable and water-insoluble characteristics, the drug-loading efficiency of the marketable PTX lipos, Lipusu, is only 6.76%...A series of in vitro/vivo experiments indicated that PTXP lipos possess colloidal stability, prolonged blood circulation, high tumor site accumulation, potent anti-tumor effects, and safety. A combination of ionizable prodrugs and remote loading has proved to be an effective and simple strategy to achieve high liposomal encapsulation efficiency of poorly soluble non-ionizable drugs for clinical application.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Safety analysis of lurbinectedin versus topotecan in elderly patients. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6374; P2, P3 With the limitations of cross-trial comparisons, lurbinectedin shows a clear advantage in terms of hematological toxicity compared with topotecan in patients ? 65 years old.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC. (On Demand | Hall A; Poster Bd # 218) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1977; P2, P3 Clinical trial information: NCT02454972, NCT02566993. >* Growth colony-stimulating factors were mandatory for both ATLANTIS treatment arms.** Nominal comparisons in ATLANTIS (small number of patients in basket trial)AEs, adverse events; CI, confidence interval; mo, months; OS, overall survival.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients (clinicaltrials.gov) - Apr 26, 2023 P1, N=28, Recruiting, Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Oct 2023 Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Dec 2024
- |||||||||| irinotecan hydrochloride liposome injection (LY01610) / Luye Group
Enrollment closed, Trial completion date, Trial primary completion date: Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer (clinicaltrials.gov) - Apr 26, 2023 P2, N=90, Active, not recruiting, Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
#Lurbinectedin (Twitter) - Apr 16, 2023
- |||||||||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, epothilone D (BMS-241027) / BMS, utidelone (UTD1) / Beijing Biostar Technologies
Review, Journal: Epothilones as Natural Compounds for Novel Anticancer Drugs Development. (Pubmed Central) - Apr 13, 2023 In recent years innovative synthetic strategies resulted in the synthesis of new epothilone derivatives with improved activity against refractory tumors with better activities when compared to ixabepilone or taxol. These compounds together with specific delivery mechanisms could be developed in anti-cancer drugs.
- |||||||||| Pozenveo (poziotinib) / Assertio
Trial completion date, Trial primary completion date, EGFR exon 20, HER2 exon 20, Metastases: NCI-2017-00831: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (clinicaltrials.gov) - Apr 5, 2023 P2, N=116, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
|